(S)-2-Amino-3-(2-(2-carboxyethyl)-4-(phenylsulfonamido)phenyl)propanoic acid

ID: ALA3337654

Chembl Id: CHEMBL3337654

PubChem CID: 118714817

Max Phase: Preclinical

Molecular Formula: C18H20N2O6S

Molecular Weight: 392.43

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  N[C@@H](Cc1ccc(NS(=O)(=O)c2ccccc2)cc1CCC(=O)O)C(=O)O

Standard InChI:  InChI=1S/C18H20N2O6S/c19-16(18(23)24)11-13-6-8-14(10-12(13)7-9-17(21)22)20-27(25,26)15-4-2-1-3-5-15/h1-6,8,10,16,20H,7,9,11,19H2,(H,21,22)(H,23,24)/t16-/m0/s1

Standard InChI Key:  AQLOKIQETOVNOS-INIZCTEOSA-N

Alternative Forms

  1. Parent:

    ALA3337654

    ---

Associated Targets(non-human)

Grik1 Glutamate receptor ionotropic kainate 1 (319 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Grik3 Glutamate receptor ionotropic kainate 3 (207 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 392.43Molecular Weight (Monoisotopic): 392.1042AlogP: 1.46#Rotatable Bonds: 9
Polar Surface Area: 146.79Molecular Species: ZWITTERIONHBA: 5HBD: 4
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 5#RO5 Violations (Lipinski):
CX Acidic pKa: 1.44CX Basic pKa: 9.47CX LogP: -0.71CX LogD: -4.06
Aromatic Rings: 2Heavy Atoms: 27QED Weighted: 0.50Np Likeness Score: -0.34

References

1. Sköld N, Nielsen B, Olsen J, Han L, Olsen L, Madsen U, Kristensen JL, Pickering DS, Johansen TN..  (2014)  Design, synthesis and in vitro pharmacology of GluK1 and GluK3 antagonists. Studies towards the design of subtype-selective antagonists through 2-carboxyethyl-phenylalanines with substituents interacting with non-conserved residues in the GluK binding sites.,  22  (19): [PMID:25172149] [10.1016/j.bmc.2014.07.045]

Source